993 results about "Quinone" patented technology

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

The invention relates to the use of an organic mesomeric compound as organic dopant for doping an organic semiconducting matrix material for varying the electrical properties thereof. In order to be able to handle organic semiconductors more easily in the production process and to be able to produce electronic components with doped organic semiconductors more reproducibly, a quinone or quinone derivative or a 1,3,2-dioxaborine or a 1,3,2-dioxaborine derivative may be used as a mesomeric compound, which under like evaporation conditions has a lower volatility than tetrafluorotetracyanoquinonedimethane (F4TCNQ).

The present invention is concerned with a method for improving blood glucose control or for preventing or treating a condition requiring increasing insulin sensitivity or reducing insulin resistance in a subject in need of such control which comprises administering to the subject a composition comprising a therapeutically effective amount of one or more quinones of Formula I.

A method of forming a minute resist pattern wherein a positive-working photoresist composition containing 3 to 15 parts by weight of a quinone diazide group-containing photosensitizer relative to 100 parts by weight of alkali-soluble novolak resin is developed by an aqueous organic or inorganic alkali solution having a lower alkali concentration than that of the conventional one as the developer. The preferable example of the organic alkali materials in the developer is quaternary ammonium hydroxide, and the preferable example of the inorganic alkali materials in the developer is alkali metal hydroxide. The concentrations of the quaternary ammonium hydroxide and the alkali metal hydroxide in the developing solution are 2.2% by weight or less and 0.4% by weight or less respectively. Using such developing solution, high sensitivity, a high film retention rate, high resolution, low process dependency of dimension accuracy, and a formation of excellent pattern profile can be achieved.

Disclosed herein is a method for inhibiting the premature polymerization of ethylenically unsaturated monomers comprising adding to said monomers an effective amount of: A) at least one nitroxyl compound, and B) at least one quinone alkide compound having an electron-withdrawing group at the 7-position. Additionally, a composition is disclosed that comprises: A) at least one nitroxyl compound, and B) at least one quinone alkide compound having an electron-withdrawing group at the 7-position.

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

The invention is a two part polymerizable composition comprising in one part an organoboron compound capable of forming free radical generating species amine complex and in the second part one or more compounds capable of free radical polymerization and a cure accelerator comprising a) at least one compound containing a quinone structure or b) at least one compound containing at least one aromatic ring and one or more, preferably two substituents on the aromatic ring selected from hydroxyl, ether and both, where there are two substituents they are located either ortho or para with respect to one another and a peroxide containing compound. The second part may further contain an agent capable of causing the organoboron compound to form free radical generating species upon contacting the two parts. The first part may further comprises one or more compounds capable of free radical polymerization. This facilitates formulating compositions that have commercially desirable volumetric ratios of the two parts. Adhesive compositions of the present formulation provide excellent adhesion to low surface energy substrates, such as plastics.

A polymerizable polymeric photoinitiator according to Formula (I):

wherein:

• • PL represents an n+m+p-functional polymeric core;
  • n and m independently represent an integer from 1 to 30;
  • p represents an integer from 0 to 10;
  • o is 0 or 1;
  • INI represents a group selected from the group consisting of a benzophenone, a thioxanthone, a carbazole, a anthraquinone, a camphor quinone, an α-hydroxyalkylphenone, an α-aminoalkylphenone, an acylphosphine oxide, a bisacyl phosphine oxide, an acylphosphine sulfide, a phenyl glyoxalate, a benzoin ether, a benzyl ketal, an α-dialkoxyacetophenone, a carbazolyl-O-acyl-oxime, an α-haloarylketone and an α-haloaryl sulfone;
  • L₃ and L₄ represent a substituted or unsubstituted divalent linking group comprising 1 to 14 carbon atoms;
  • A represents a radically polymerizable functional group selected from the group consisting of an acrylate, a methacrylate, a styrene, an acryl amide, a methacryl amide, a maleate, a fumarate, an itaconate, an vinyl ether, an allyl ether, an allyl ester, a maleimide, a vinyl nitrile and a vinyl ester; and
  • R4 represents a substituted or unsubstituted alkyl group.

Radiation curable compositions containing the polymerizable polymeric photoinitiator and methods for preparing the polymerizable polymeric photoinitiator are also disclosed.

The invention provides a blood sugar biosensor of carbon nanometer tube, it includes floor, three electrode system, insulation, forming the reaction lumen body around three electrode system, setting the conversion zone in the reaction lumen body, laying over the cover plate on the reaction lumen body, the conversion zone includes, enzyme and electron transport agent, the enzyme is the glc dh pyrrole and quinone for coenzyme. The transducer's corresponding sensitivity improves evidently, it has not infection for measuring the dextrose deepness in the blood with the oxygen pressure, thickness in the measuring site and oxygen content of blood sample. The invention has the excellence of easy manufacture artwork, low cost, suited to volume-produce and the low sample quantity etc.

Compounds having quinone and quinone analogs useful for pharmaceutical preparations have now been found which inhibit cysteine proteases, in particular, caspases and 3C-cysteine proteases. The cysteine protease inhibitors of the present invention can be identified by their mode of action in disrupting the ability of cysteine proteases and, in particular, caspases to cleave a peptide chain. These compounds are useful in inhibiting cysteine protease or cysteine protease-like proteins and for treating infections diseases or physiopathological diseases or disorders attributed to the presence of excessive or insufficient levels of cysteine proteases.

A positive photosensitive resin precursor composition which can be can be developed in an alkaline developer is provided. The positive photosensitive resin precursor composition comprises (a), one of (b1) and (b2), and (c): (a) a polyamic acid ester and/or a polyamic acid polymer, both of which are soluble in an alkaline aqueous solution; (b1) a phenolic-hydroxyl-group-containing thermally crosslinkable compound comprising an organic-group-R<superscript>1>-substituted methylol group represented by formula (1) (wherein R<superscript>1 >is not a hydrogen atom),CH<subscript>2</highlight>-OR<superscript>1>) (1);(b2) a thermally crosslinkable compound containing a ureal organic group substituted by an organic group R<superscript>1 >and represented by formula (2) (c) an esterified quinone diazide compound.

The Holographic Beam Combiner, (HBC), is used to combine the output from many lasers into a single-aperture, diffraction-limited beam. The HBC is based on the storage of multiple holographic gratings in the same spatial location. By using a photopolymer material such as quinone-doped polymethyl methacrylate (PMMA) that uses a novel principle of “polymer with diffusion amplification” (PDA), it is possible to combine a large number (N) of diode lasers, with an output intensity and brightness 0.9 N times as much as those of the combined outputs of individual N lasers. The HBC will be a small, inexpensive to manufacture, and lightweight optical element. The basic idea of the HBC is to construct multiple holograms onto a recording material, with each hologram using a reference beam incident at a different angle, but keeping the object beam at a fixed position. When illuminated by a single read beam at an angle matching one of the reference beams, a diffracted beam is produced in the fixed direction of the object beam. When multiple read beams, matching the multiple reference beams are used simultaneously, all the beams can be made to diffract in the same direction, under certain conditions that depend on the degree of mutual coherence between the input beams.

Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.

Disclosed is a positive-type photosensitive resin composition comprising: (a) an alkali-soluble resin; (b) a quinone diazide compound; (c) a heatsensitive compound which colors upon being heated and which shows an absorption maximum at a wavelength of not less than 350 nm and not more than 700 nm; and (d) a compound which does not have an absorption maximum at a wavelength of not less than 350 nm to less than 500 nm, and has an absorption maximum at a wavelength of not less than 500 nm and not more than 750 nm. The composition is preferably used for forming light-blocking separators or black matrices of organic electroluminescent devices and liquid crystal display elements.

Methods of treating or suppressing oxidative stress disorders affecting normal electron flow in the cells, including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases, diseases of aging and diseases caused by reactive oxygen species are disclosed, as well as compounds useful in the methods of the invention, such as such as catechol or ortho-quinone derivatives of Formula (I).

Methods of modulating, adjusting, and maintenance of the glutathione redox status of an individual, or cell, tissues, bodily fluids, or body compartments of the individual, are disclosed, as are compositions suitable for such modulating, adjusting, and maintenance. The modulation or adjustment is achieved by altering the amounts of reduced glutathione versus oxidized glutathione in the individual, or cells, tissues, bodily fluids, or body compartments of the individual. Modulation, adjustment, and maintenance of the redox status of an individual enables treatment, prevention or suppression of diseases or symptoms associated with diseases. These methods are achieved by using quinone derivatives.

A method for preparing a nontoxic composition that includes an extract of Larrea tridentata plant material and is substantially free of nordihydroguaiaretic acid (NDGA) quinone includes the steps of mixing the Larrea tridentata plant material with an aqueous solvent to produce an extract, and reducing any NDGA quinone in the extract to NDGA. A method for treating an infection from a virus includes the step of administering to a human in need thereof a pharmaceutical composition comprising an extract of Larrea tridentata in an amount that is effective to suppress NF-kB activation. An antimicrobial solution includes an aqueous solvent, and an extract of Larrea tridentata plant material. A formulation for medical and health products includes an extract of Larrea tridentata plant material, and at least one detoxification enhancer that functions as a chemoprotective agent.

The present invention relates to methods of treating methylmalonic aciduria and other organic acidurias with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.